These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 24166706)

  • 1. The role of primary pharmacological therapy in acromegaly.
    Espinosa de los Monteros AL; Carrasco CA; Albarrán AA; Gadelha M; Abreu A; Mercado M
    Pituitary; 2014 Jan; 17 Suppl 1(Suppl 1):S4-10. PubMed ID: 24166706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological management of acromegaly: a current perspective.
    Manjila S; Wu OC; Khan FR; Khan MM; Arafah BM; Selman WR
    Neurosurg Focus; 2010 Oct; 29(4):E14. PubMed ID: 20887124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Novel pharmacologic therapies in acromegaly].
    Góth M; Hubina E; Kovács L; Szabolcs I
    Orv Hetil; 2002 May; 143(19 Suppl):1057-62. PubMed ID: 12063860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy.
    Ferone D; Pivonello R; Lastoria S; Faggiano A; Del Basso de Caro ML; Cappabianca P; Lombardi G; Colao A
    Clin Endocrinol (Oxf); 2001 Apr; 54(4):469-77. PubMed ID: 11318782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological approach to the treatment of acromegaly.
    Ezzat S
    Neurosurg Focus; 2004 Apr; 16(4):E3. PubMed ID: 15191332
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cabergoline in acromegaly.
    Kuhn E; Chanson P
    Pituitary; 2017 Feb; 20(1):121-128. PubMed ID: 28025719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: a retrospective clinical study and review of the literature.
    Suda K; Inoshita N; Iguchi G; Fukuoka H; Takahashi M; Nishizawa H; Yamamoto M; Yamada S; Takahashi Y
    Endocr J; 2013; 60(4):507-15. PubMed ID: 23291436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status.
    Cozzi R; Attanasio R; Lodrini S; Lasio G
    Clin Endocrinol (Oxf); 2004 Aug; 61(2):209-15. PubMed ID: 15272916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and limits of somatostatin analogs.
    Petersenn S
    J Endocrinol Invest; 2005; 28(11 Suppl International):53-7. PubMed ID: 16625846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medical treatment of acromegaly: comorbidities and their reversibility by somatostatin analogs.
    Tolis G; Angelopoulos NG; Katounda E; Rombopoulos G; Kaltzidou V; Kaltsas D; Protonotariou A; Lytras A
    Neuroendocrinology; 2006; 83(3-4):249-57. PubMed ID: 17047390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world value of cabergoline in the treatment of acromegaly.
    Shimon I
    Best Pract Res Clin Endocrinol Metab; 2024 Jul; 38(4):101887. PubMed ID: 38443225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Optimization of the medical treatment for acromegaly].
    Díez JJ; Iglesias P
    Med Clin (Barc); 2013 Apr; 140(8):360-5. PubMed ID: 23103101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cabergoline in the treatment of acromegaly: a study in 64 patients.
    Abs R; Verhelst J; Maiter D; Van Acker K; Nobels F; Coolens JL; Mahler C; Beckers A
    J Clin Endocrinol Metab; 1998 Feb; 83(2):374-8. PubMed ID: 9467544
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of Dopamine Agonists in Pituitary Adenomas.
    Giraldi EA; Ioachimescu AG
    Endocrinol Metab Clin North Am; 2020 Sep; 49(3):453-474. PubMed ID: 32741482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short- and long-term efficacy of combined cabergoline and octreotide treatment in controlling igf-I levels in acromegaly.
    Mattar P; Alves Martins MR; Abucham J
    Neuroendocrinology; 2010; 92(2):120-7. PubMed ID: 20802256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New perspectives in the medical treatment of acromegaly.
    Colao A; Pivonello R; Auriemma RS; Galdiero M; Guerra E; Milone F; De Leo M; Lombardi G
    J Endocrinol Invest; 2005; 28(11 Suppl International):58-66. PubMed ID: 16625847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of high-dose long-acting repeatable octreotide as monotherapy or in combination with pegvisomant or cabergoline in patients with acromegaly not adequately controlled by conventional regimens: results of an open-label, multicentre study.
    Colao A; Zgliczyński W; Komorowski J; Kos-Kudła B; Tabarin A; Kerlan V; Minuto FM; Scaroni C; Bolanowski M
    Endokrynol Pol; 2019; 70(4):305-312. PubMed ID: 31274183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical treatment of acromegaly - When the tumor size matters: A narrative review.
    Doknic M; Stojanovic M; Miljic D; Milicevic M
    Growth Horm IGF Res; 2024 Oct; 78():101608. PubMed ID: 39116789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage.
    Cozzi R; Montini M; Attanasio R; Albizzi M; Lasio G; Lodrini S; Doneda P; Cortesi L; Pagani G
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1397-403. PubMed ID: 16449332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New medical therapies of acromegaly.
    Maffezzoni F; Frara S; Doga M; Mazziotti G; Giustina A
    Growth Horm IGF Res; 2016; 30-31():58-63. PubMed ID: 27745780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.